Arisinfra Solutions Limited has announced the grant of employee stock options under its Employee Stock Option Plan 2024, marking a significant step in its employee incentive program. The company's Nomination and Remuneration Committee approved this initiative during a meeting held on January 30, 2026.

ESOP Grant Details

The committee approved the grant of 17,755 employee stock options with a total value of ₹43,50,000 under the 'Arisinfra Solutions Limited - Employee Stock Option Plan - 2024'. The meeting commenced at 02:10 p.m. (IST) and concluded at 02:30 p.m. (IST), with the resolution being passed to formalize this employee benefit scheme.

Scheme Structure and Compliance

Each stock option entitles the option holder to apply for one equity share of the company valued at ₹2 each. The scheme operates in full compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The exercise price per option will be determined by the Board of Directors or the Nomination and Remuneration Committee, with the condition that it shall not be less than the face value of the equity share as on the date of grant.

Current Status and Exercise Framework

As of the grant date, no options have been vested or exercised, which is typical for newly granted employee stock options. The specific exercise price will be communicated to option grantees through individual grant letters at the time of grant. The time frame for option exercise will be governed by the terms outlined in the Arisinfra ESOP - 2024 plan.

Regulatory Compliance and Documentation

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, read with SEBI Master Circular dated November 11, 2024. The intimation has been filed with both BSE Limited and National Stock Exchange of India Limited, and the information is also available on the company's website at their investor relations section. This ESOP grant represents Arisinfra Solutions' commitment to employee retention and motivation through equity participation.

ArisInfra Solutions Limited has submitted its monitoring agency report for the quarter ended December 31, 2025, under SEBI Regulation 32(6) regarding the utilization of IPO proceeds. The report, prepared by ICRA Limited as the appointed monitoring agency, confirms that the company's fund utilization remains aligned with the disclosed objects of the issue without any material deviations.

Issue Details and Proceeds

The company completed its Initial Public Offer during June 18-20, 2025, raising INR 499.596 crore. Additionally, a Pre-IPO placement contributed INR 80.004 crore, bringing the total monitored proceeds to INR 579.60 crore for Q3FY26.

The actual net proceeds exceeded the prospectus estimate by INR 7.429 crore due to lower-than-expected issue-related expenses, which decreased from INR 38.154 crore to INR 30.725 crore.

Fund Utilization Objectives

The IPO proceeds are being deployed across four primary objectives as outlined in the offer document:

The revision in general corporate purposes allocation from INR 31.842 crore to INR 39.271 crore represents the unutilized expense amount being redirected as permitted under the offer document terms.

Quarterly Progress and Deployment

During Q3FY26, the company utilized INR 25.465 crore from IPO proceeds across various objectives. The total unutilized IPO amount stands at INR 11.833 crore as of December 31, 2025. For Pre-IPO proceeds, the company reported negative net utilization during the quarter due to refunds totaling INR 11.000 crore, including:

• INR 1.000 crore refund from management deposit with Natureresidences Real Estate Development Private Limited
• INR 10.000 crore full refund of earnest money deposit from Call Express Construction

Investment of Unutilized Funds

The company has deployed unutilized proceeds in term deposits and maintains balances across various designated accounts:

IPO Proceeds Deployment:

Pre-IPO Proceeds Deployment:

Compliance and Timeline Status

ICRA Limited confirmed that all utilization aligns with offer document disclosures, with no shareholder approval required for deviations. The monitoring agency reported no unfavorable events affecting project viability and confirmed that all statutory approvals have been obtained. All objects remain on schedule according to the planned timeline, with debt repayment and general corporate purposes targeted for FY2026, while working capital funding extends through FY2027.

The report demonstrates the company's adherence to regulatory requirements and transparent deployment of raised capital according to stated objectives, providing investors with detailed visibility into fund utilization progress.